Carbamazepine toxicity: Difference between revisions
(Created page with "==Background== *Has anticholinergic in addition to antiepileptic effects *Therapeutic concentration: 4-12 ==Clinical Features== *May be delayed and follow crescendo-decrescendo ...") |
Elcatracho (talk | contribs) |
||
| (30 intermediate revisions by 9 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Has anticholinergic | *Has [[Anticholinergic Toxicity|anticholinergic]], sodium-channel blockade, anti-NMDA and antiepileptic effects | ||
*Therapeutic concentration: 4-12 | *Therapeutic concentration: 4-12 mg/L | ||
==Clinical Features== | ==Clinical Features== | ||
''May be delayed and follow crescendo-decrescendo course (due to delayed GI motility)'' | |||
* | *Neurologic | ||
**Ataxia | **[[Ataxia ]] | ||
**Nystagmus | **Nystagmus | ||
**Coma | **[[Seizures]] | ||
*Anticholinergic | **[[Coma ]] | ||
* | *[[Anticholinergic Toxicity]] | ||
**Dysrhythmias are rare but may occur | *Cardiovascular | ||
** | **Dysrhythmias are rare but may occur | ||
**[[Wide QRS]] from sodium channel blockade<ref>Novartis Pharmaceuticals USA. Prescribing information for Tegretol CR400(R) tablets www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (Accessed on August 27, 2008).</ref> | |||
**[[QT Prolongation]] | |||
==Diagnosis== | ==Differential Diagnosis== | ||
== | ==Evaluation== | ||
*GI | *Levels do not accurately correlate with clinical severity | ||
**Activated | |||
*Dialysis | ==Management== | ||
*GI decontamination | |||
**[[Activated Charcoal]] (if presents within 1hr of ingestion) | |||
**Consider [[Multidose activated charcoal]] | |||
*[[Dialyzable Drugs|Dialysis]] for severe cases. Indications: <ref>Ghannoum M, Yates C, Galvao TF et al. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Tox 2016. 52(10):993-1004.</ref> | |||
**Intractable seizures or life threatening dysrhythmia (level 1D recommendation) | |||
**Respiratory depression requiring mechanical ventilation or prolonged coma (level 2D suggestion) | |||
**Significant toxicity or rising/persistent carbamazepine level despite [[activated charcoal]] and supportive care (level 2D suggestion) | |||
==Disposition== | ==Disposition== | ||
*Consider | *Consider discharge for patient with decreasing levels (measured few hrs apart) and is asymptomatic | ||
==See Also== | |||
*[[Toxicology (main)]] | |||
*[[Carbamazepine]] | |||
==References== | |||
<references/> | |||
[[Category: | [[Category:Toxicology]] | ||
Latest revision as of 23:35, 11 February 2021
Background
- Has anticholinergic, sodium-channel blockade, anti-NMDA and antiepileptic effects
- Therapeutic concentration: 4-12 mg/L
Clinical Features
May be delayed and follow crescendo-decrescendo course (due to delayed GI motility)
- Neurologic
- Anticholinergic Toxicity
- Cardiovascular
- Dysrhythmias are rare but may occur
- Wide QRS from sodium channel blockade[1]
- QT Prolongation
Differential Diagnosis
Evaluation
- Levels do not accurately correlate with clinical severity
Management
- GI decontamination
- Activated Charcoal (if presents within 1hr of ingestion)
- Consider Multidose activated charcoal
- Dialysis for severe cases. Indications: [2]
- Intractable seizures or life threatening dysrhythmia (level 1D recommendation)
- Respiratory depression requiring mechanical ventilation or prolonged coma (level 2D suggestion)
- Significant toxicity or rising/persistent carbamazepine level despite activated charcoal and supportive care (level 2D suggestion)
Disposition
- Consider discharge for patient with decreasing levels (measured few hrs apart) and is asymptomatic
See Also
References
- ↑ Novartis Pharmaceuticals USA. Prescribing information for Tegretol CR400(R) tablets www.pharma.us.novartis.com/product/pi/pdf/tegretol.pdf (Accessed on August 27, 2008).
- ↑ Ghannoum M, Yates C, Galvao TF et al. Extracorporeal treatment for carbamazepine poisoning: Systematic review and recommendations from the EXTRIP workgroup. Clin Tox 2016. 52(10):993-1004.